Document Detail

Clinical pharmacology of portal hypertension.
MedLine Citation:
PMID:  20951924     Owner:  NLM     Status:  MEDLINE    
Portal hypertension is an increase in pressure in the portal vein and its tributaries. It is defined as a portal pressure gradient (the difference in pressure between the portal vein and the hepatic veins) greater than 5 mm Hg. Although this gradient defines portal hypertension, a gradient of 10 mm Hg or greater defines clinically significant portal hypertension, because this pressure gradient predicts the development of varices, decompensation of cirrhosis, and hepatocellular carcinoma. The most direct consequence of portal hypertension is the development of gastroesophageal varices that may rupture and lead to the development of variceal hemorrhage. This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage.
Cecilia Miñano; Guadalupe Garcia-Tsao
Related Documents :
17318504 - Evaluation of the cck-4 model as a challenge paradigm in a population of healthy volunt...
18445644 - Mechanisms of extrahepatic vasodilation in portal hypertension.
15094704 - A randomized study of losartan vs propranolol: effects on hepatic and systemic hemodyna...
4087374 - Electronmicroscopic autoradiographic study of the distribution of 3h-diltiazem in myoca...
10981074 - The role of the central nervous system in hypertension.
8994484 - Predictors of pressure ulcer healing among long-term care residents.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Gastroenterology clinics of North America     Volume:  39     ISSN:  1558-1942     ISO Abbreviation:  Gastroenterol. Clin. North Am.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-10-18     Completed Date:  2011-02-04     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  8706257     Medline TA:  Gastroenterol Clin North Am     Country:  United States    
Other Details:
Languages:  eng     Pagination:  681-95     Citation Subset:  IM    
Copyright Information:
Published by Elsevier Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / administration & dosage,  therapeutic use
Fibrosis / complications
Hemorrhage / drug therapy,  prevention & control,  surgery
Hypertension, Portal / drug therapy*,  etiology,  physiopathology*
Liver / blood supply
Randomized Controlled Trials as Topic
Somatostatin / administration & dosage,  analogs & derivatives,  therapeutic use
Varicose Veins / physiopathology,  prevention & control
Vasoconstrictor Agents / therapeutic use
Vasodilator Agents / therapeutic use
Vasopressins / administration & dosage,  therapeutic use
Grant Support
K24 DK002727/DK/NIDDK NIH HHS; K24 DK002727-10/DK/NIDDK NIH HHS; P30 DK034989/DK/NIDDK NIH HHS; P30 DK034989-277468/DK/NIDDK NIH HHS
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Vasoconstrictor Agents; 0/Vasodilator Agents; 11000-17-2/Vasopressins; 51110-01-1/Somatostatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New pharmacologic therapies in chronic hepatitis B.
Next Document:  Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and col...